Science You Can Trust. Evidence Behind Every Therapy.
Medical Studies
– Evidence Library
We base all our treatments on peer-reviewed medical studies (FDA, NEJM, JAMA, Nature, Lancet, PubMed). Explore the evidence and see how our therapies deliver real patient benefits.
Initial consultation is completely free and without obligation.
Testosterone Replacement Therapy — Medical Studies
In appropriately diagnosed men with hypogonadism, testosterone therapy improves sexual function, corrects anemia, and increases bone density, with cardiovascular safety supported by a large outcomes trial.
Featured Studies
● Improved sexual function & libido — NEJM 2016 (T-Trials).
● Corrects anemia & prevents new cases — JAMA Network Open 2023 (TRAVERSE Anemia).
● Bone mineral density & strength ↑ (spine & hip) — JAMA Internal Medicine 2017.
● Cardiovascular safety confirmed (non-inferior to placebo on MACE) — NEJM 2023 (TRAVERSE).
More Studies
● Comprehensive safety meta-analysis: Individual-patient and aggregate-data meta analysis found no excess in major cardiovascular events or mortality during testosterone treatment (monitor hematocrit/erythrocytosis). — The Lancet Healthy Longevity 2022. thelancet.com
● Prevention of type 2 diabetes (T4DM RCT): In at-risk men on a lifestyle program, 2-year testosterone reduced progression to diabetes vs placebo. — Lancet Diabetes & Endocrinology 2021. PubMed
● Fat loss with lean-mass preservation (RCT): During a hypocaloric diet, testosterone produced greater fat-mass loss with preserved lean mass vs placebo. — BMC Medicine 2016. BioMed Central
● Sexual activity, desire & erectile function (meta-analysis): Improvements in libido, erectile function, and satisfaction in hypogonadal men. — Journal of Clinical Endocrinology & Metabolism 2018. Oxford Academic
● Functional benefits (broad SR/MA): A network meta-analysis (87 RCTs + 51 non-randomized studies) showed improvements vs placebo in QoL, libido, depressive symptoms, and erectile function; most trials were short and with some risk of bias (note for transparency). PMC+1
● Erectile function + lower urinary tract safety (recent MA): A 2024 meta-analysis found IIEF improvement without adverse changes in IPSS, PSA, prostate volume, Qmax, or PVR, across routes/durations. Frontiers+1
● Route of injection: Peer-reviewed review articles show subcutaneous (SC) testosterone esters have PK profiles comparable to IM and are acceptable for self-administration when taught properly. (This supports offering SC as an option in clinic SOPs.) PMC+1
Initial consultation is completely free and without obligation.
Cryotherapy — Medical Studies
Whole-/partial-body cryotherapy (WBC/PBC) reduces post-exercise muscle soreness, supports faster neuromuscular recovery, and shows favorable inflammation signals when applied with rigorous temperature and safety protocols.
Featured Studies
● Best option for post-exercise soreness & neuromuscular recovery — Systematic review & network meta-analysis (2024). PMC
● Muscle soreness ↓ and recovery ↑ after exercise-induced muscle damage — Systematic review & meta-analysis (2022). PMC
● Acute recovery after a high-intensity training day (elite rowers, randomized) — Frontiers in Physiology trial (2024). PMC
● Lower systemic inflammation (hsCRP) with repeated WBC — Journal of Medical Internet Research (2024). PMC
More Studies
● Anti-inflammatory profile (human RCT meta-analysis): IL-1β ↓, IL-10 ↑ — Scientific Reports meta-analysis (2025). PubMed
● Pre-exercise WBC blunts damage markers after eccentric work — Frontiers in Physiology study (2024). Frontiers
● WBC vs PBC — both effective for DOMS reduction — Systematic review & meta-analysis (2022). PMC
● Practical protocol context (temperatures, exposures, safety considerations) — International scoping review on WBC safety (2023). PMC
Initial consultation is completely free and without obligation.
Peptides Therapy — Medical Studies
Evidence-based peptide therapies—especially GLP-1 and dual GIP/GLP-1 agonists— deliver substantial, sustained weight loss and cardiometabolic improvements; selected peptides also show anti-inflammatory effects and support faster recovery under medical supervision.
Featured Studies
● ~15% body-weight loss in adults with overweight/obesity — Semaglutide 2.4 mg + lifestyle — NEJM 2021 (STEP-1). New England Journal of Medicine
● Superior weight reduction vs placebo — Tirzepatide 5/10/15 mg — NEJM 2022 (SURMOUNT-1). New England Journal of Medicine
● Weight-regain prevention with ongoing therapy — Continued semaglutide maintained/extended loss vs withdrawal — JAMA 2021 (STEP-4). jamanetwork.com
● Long-term efficacy maintained (2 years) — Semaglutide 2.4 mg — Nature Medicine 2022 (STEP-5). Nature
More Studies
● Visceral fat ↓ & liver fat ↓; quality of life signals ↑ (tesamorelin) — NEJM 2007 and JAMA 2014.
New England Journal of Medicine+1
● Improved erectile function (bremelanotide / PT-141) — Double-blind trial (2004) and co-
administration study with sildenafil (2005): PubMed 2004 • PubMed 2005. PubMed+1
● Growth hormone / IGF-1 ↑ (CJC-1295; human data) — JCEM 2006. Oxford Academic
● Skin healing, collagen & hair (GHK-Cu; review) — IJMS 2018 Review. PMC
● Tissue-healing & anti-inflammatory signals (BPC-157; preclinical) — Overview + pharmacokinetics:
Frontiers Review 2021 • Frontiers Pharmacology 2022 PK. Frontiers+1
Initial consultation is completely free and without obligation.
ED Shockwave (LI-ESWT) — Medical Studies
Shockwave therapy for reliable erections — gentle, no surgery. Low-intensity acoustic waves boost microcirculation, support natural tissue regeneration, and are well tolerated. Clinical studies show many men with blood-flow–related erectile dysfunction experience firmer, more spontaneous erections with lasting results.
Featured Studies
● Improvements that persist beyond the treatment period — Systematic review (2019, Int J Impot Res, PubMed).
● Consistent erectile-function gains across different energy settings and session schedules — Meta-analysis (2017, J Sex Med, PubMed).
More Studies
● Randomized evidence pooled (16 trials): clinically meaningful improvements versus sham — Meta-analysis (2022, Am J Men’s Health, PMC).
● Updated synthesis through 2024: overall effectiveness with low adverse-event rates when protocols are applied correctly — Overview of systematic reviews/meta-analyses (2024, PMC).
● Comprehensive analysis of randomized trials: significant erectile-function improvements versus sham — Meta-analysis (2025, PMC).
● Protocol insights tied to outcomes (e.g., ~1,500 shocks per session, ~0.09 mJ/mm², ~5 Hz) — World Journal of Men’s Health (2024).
Initial consultation is completely free and without obligation.
Stem Cell Therapy — Medical Studies
Intra-articular mesenchymal stem cell therapy for knee osteoarthritis can reduce pain, improve function, and may slow structural cartilage loss, with an overall reassuring safety profile under medical supervision.
Featured Studies
● Less knee pain and better function at 6 and 12 months — Meta-analysis (2025, open access). PMC
● Phase III randomized, double-blind, multicenter trial: less pain and better function vs placebo (261 patients) — Kim et al., 2023. PubMed
● Slower cartilage loss on 3D MRI after synovial MSC injections — Clinical study (2021, open access). PMC
More Studies
● Dose-focused meta-analysis of randomized trials: significant improvements in pain (VAS) and function (Western Ontario and McMaster Universities Osteoarthritis Index) at 6–12 months; acceptable safety — Rahmadian et al., 2025. PMC
● Allogeneic adipose-derived MSCs (phase II, triple-blind, placebo-controlled): clinically meaningful improvement with good safety — Sadri et al., 2023. PMC
● Bone marrow–derived MSCs vs hyaluronic acid (randomized): better quality of life and lower pain; MRI T2 changes favored MSCs — Clinical trial (2022). PubMed
● Comparative ranking across cell sources and doses: autologous bone-marrow MSCs ranked highest for pain and range-of-motion; umbilical-cord MSCs best on MRI score; adipose-derived MSCs best on WOMAC-positive patients — Network meta-analysis (2024). BioMed Central
Initial consultation is completely free and without obligation.
IV Therapy — Medical Studies
Carefully selected IV therapies (e.g., Vitamin C, Myers’ Cocktail, IV glutathione) show rapid fatigue relief in some settings, symptom improvements in select conditions, and generally reassuring short-term safety under medical supervision. Featured studies
Featured Studies
● Rapid fatigue reduction within 2–24 hours (IV Vitamin C, double-blind RCT) — Suh et al., 2012. Nutrition Journal.
● 3 of 4 controlled trials show fatigue improvement with IV Vitamin C — Systematic Review focused on post-viral/long-COVID feasibility, 2021. Nutrients.
● Myers’ Cocktail: safety & feasibility; symptom relief vs baseline (pilot RCT, fibromyalgia) — Ali et al., 2009. (Placebo difference not statistically significant; safety supported.)
More Studies
● Vitamin C in COVID-19: some meta-analyses show signals (e.g., mortality in RCTs) but results are mixed; regimen matters — Nutrients 2022.
● Long-COVID & acute COVID: meta-analyses show neutral effects on mortality/LOS but highlight importance of timing and duration — Frontiers in Nutrition 2024.
● Mechanistic/clinical overview: High-dose IV Vitamin C and symptoms (fatigue, cognition, pain) in oxidative-stress conditions — Review 2022.
● Methodological note: Possible “rebound” if Vitamin C is stopped abruptly in acute settings — Frontiers in Medicine 2024.
Initial consultation is completely free and without obligation.
NAD⁺ — Medical Studies
NAD⁺ precursors (NR, NMN) reliably raise NAD⁺ levels in humans and show promising functional benefits in select groups (e.g., improved vascular function and walking endurance in PAD, strength/speed signals in older adults) with good short-term safety, including high-dose NR.
More Studies
● Narrative/Mechanistic overview: NAD⁺ in regenerative medicine and aging biology — Conlon et al., 2021. PMC review.
● State-of-the-science review (2024): clinical signals and trial landscape for NMN/NR — Iqbal et al., 2024. Biochimica et Biophysica Acta.
● Systematic review of NMN RCTs (2024): generally well-tolerated; mixed but promising functional outcomes — Cureus 2024.